Compounds > 1-hydroxymethylmidazolam glucuronide
Page last updated: 2024-11-07

1-hydroxymethylmidazolam glucuronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-hydroxymethylmidazolam glucuronide: metabolite of midazolam [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-hydroxymidazolam beta-D-glucuronide : A beta-D-glucosiduronic acid that is beta-D-glucuronic acid in which the anomeric hydroxyl hydrogen has been replaced by a 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-4-yl group. It is the glucuronidated conjugate of the midazolam metabolite, 1-hydroxymidazolam. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID133640
CHEBI ID145334
MeSH IDM0171255

Synonyms (21)

Synonym
beta-d-glucopyranosiduronic acid, (8-chloro-6-(2-fluorophenyl)-4h-imidazo(1,5-a)(1,4)benzodiazepin-1-yl)methyl
unii-3eyb2r97a9
mdz-glucuronide
1-hydroxymethylmidazolam glucuronide
1-hydroxymidazolam beta-d-glucuronide
1'-hydroxymidazolam beta-d-glucuronide
[8-chloro-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methyl beta-d-glucopyranosiduronic acid
1'-hydroxymidazolam-glucuronide
81256-81-7
1-hydroxymidazolam glucuronide
CHEBI:145334
1'-oh mdz glucuronide
(2s,3s,4s,5r,6r)-6-[[8-chloro-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
1'-hydroxymidazolam .beta.-d-glucuronide
[8-chloro-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methyl-.beta.-d-glucopyranosiduronic acid
ICIUMXQTLQXWGL-QMDPOKHVSA-N
[8-chloro-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methyl hexopyranosiduronic acid
DTXSID301001880
1'-hydroxy midazolam-beta-d-glucuronide
1'-hydroxy midazolam-?-d-glucuronide
PD021375

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic parameters of 16 patients in the intensive care unit, sedated with midazolam, were evaluated."( Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients.
Dirksen, MS; Driessen, JJ; Guelen, PJ; Hafkenscheid, JC; Janssen, TJ; Shimoda, M; Termond, EF; van Dalen, R; Vree, TB, 1989)		0.28
"Prospective population pharmacokinetic study."( Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA, 2003)		0.32
" A population analysis was conducted via a two-compartment pharmacokinetic model by the NPEM program."( Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA, 2003)		0.32
"We describe population and individual midazolam pharmacokinetic parameter estimates in pediatric intensive care patients by using a population modeling approach."( Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA, 2003)		0.32
" Based on our findings that there is no relationship between pharmacokinetic parameters and pharmacodynamic outcome, we recommend that midazolam dosing should be titrated according to the desired clinical effect in combination with a validated assessment instrument, eg, the COMFORT scale."( Pharmacodynamics of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; Joosten, KF; van den Anker, JN; van Dijk, M; Vinks, AA, 2005)		0.33
"We aim to evaluate the influence of covariates, including cytochrome P450 3A (CYP3A) genetic polymorphisms, on the pharmacokinetics of midazolam (MDZ) in Asian cancer patients, using a population pharmacokinetic approach."( CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Goh, BC; Hee, KH; Lee, LS; Sapari, NS; Seng, KY; Soon, GH; Soong, R, 2014)		0.4
" To find clinically relevant parameters for dose individualization, we performed a pharmacokinetic study on midazolam, 1OH-midazolam (1-OH-M) and 1OH-midazolam-glucuronide (1-OH-MG) in terminally ill patients."( Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017)		0.46
"2), a population pharmacokinetic analysis was conducted with 192 samples from 45 terminally ill patients who received midazolam either orally or subcutaneously."( Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017)		0.46

Dosage Studied

ExcerptRelevanceReference
" In 20 of the 21 patients midazolam dosing could be effectively titrated to the desired level of sedation, assessed by the COMFORT scale."( Pharmacodynamics of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; Joosten, KF; van den Anker, JN; van Dijk, M; Vinks, AA, 2005)		0.33
"Our study indicates albumin levels and eGFR as relevant clinical parameters to optimize midazolam dosing in terminally ill patients."( Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017)		0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
drug metabolitenull
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
beta-D-glucosiduronic acidA glucosiduronic acid resulting from the formal condensation of any substance with beta-D-glucuronic acid to form a glycosidic bond.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
imidazobenzodiazepineAny organic heterotricyclic compound that is any benzodiazepine which is ortho-fused with a imidazole.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.36 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		5.5763imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
1-hydroxymethylmidazolam
1-hydroxymethylmidazolam: metabolite of midazolam. 1-hydroxymidazolam : An imidazobenzodiazepine that is midazolam in which one of the hydrogens of the methyl group is substituted by a hydroxy group. It is the major metabolite of the anesthetic, midazolam.		4.732aromatic primary alcohol;
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		drug metabolite;
human blood serum metabolite;
human urinary metabolite
bilirubin
[no description available]		3.4811biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.4811
Benign Neoplasms
[description not available]		03.4811
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.4811
Hypoalbuminemia
A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).		03.5311
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		02.0110
Hepatic Failure
[description not available]		02.0110
Liver Failure
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)		02.0110
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		02.0110
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		0210